Arch Therapeutics, Inc.
ARTH · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -3% | -30.5% | 16.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 31.8% | 32.4% | 48.5% | 41.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $1 | $1 | $1 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $2 | $1 |
| Operating Income | -$1 | -$1 | -$1 | -$1 |
| % Margin | -3,304.4% | -2,751.3% | -3,258.7% | -3,362.9% |
| Other Income/Exp. Net | -$5 | -$1 | -$1 | -$1 |
| Pre-Tax Income | -$6 | -$1 | -$3 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$6 | -$1 | -$3 | -$2 |
| % Margin | -18,292.2% | -4,610.4% | -5,846.6% | -6,218.1% |
| EPS | -1.44 | -0.33 | -0.57 | -0.52 |
| % Growth | -336.4% | 42.1% | -9.6% | – |
| EPS Diluted | -1.44 | -0.33 | -0.57 | -0.52 |
| Weighted Avg Shares Out | 4 | 4 | 5 | 5 |
| Weighted Avg Shares Out Dil | 4 | 4 | 5 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$5 | -$1 | -$1 | -$1 |
| % Margin | -16,117.4% | -2,749.6% | -3,257.3% | -3,361.3% |